Meheco Unit's Angina Tablets Passes Chinese Drug Regulator's Consistency Evaluation

MT NewswiresDec 23 01:40 ET

Meheco Unit's Sepsis Drug Included in China's Centralized Procurement Bid

MT NewswiresDec 16 00:01 ET

China Meheco Group (600056.SH): Sodium piperacillin for injection is expected to be selected for centralized procurement.

China Meheco Group (600056.SH) announced that on December 12, 2024, its subsidiary in Hainan...

Zhitong FinanceDec 13 06:13 ET

Meheco Receives Nod for Influenza Drug's Registration

MT NewswiresDec 5 01:41 ET

China Meheco Group (600056.SH): Subsidiary obtained pharmaceutical registration approval.

On December 4th, Gelonghui reported that China Meheco Group (600056.SH) announced that its wholly-owned subsidiary, Tianfang Pharmaceuticals Co., Ltd. (referred to as "Tianfang Pharmaceuticals"), received an approved pharmaceutical registration certificate from the National Medical Products Administration for a phosphor oseltamivir capsule (referred to as "the pharmaceutical"). Phosphor oseltamivir is a precursor drug of its active metabolite (oseltamivir carboxylate), which is a selective neuraminidase inhibitor for influenza viruses.

Gelonghui FinanceDec 4 03:48 ET

Xinkangjie: From January to August 2024, the sales scale of pharmaceuticals in the china meheco group retail market reached 324.4 billion yuan, with a year-on-year growth of 1.4%.

In terms of distribution channels, the scale of retail pharmacies (including O2O) accounts for 87.0%, with a year-on-year growth rate of 0.3%; the scale of e-commerce B2C accounts for 13.0%, with a year-on-year growth rate of 9.6%, and the scale proportion has increased by 1.0% year-on-year, highlighting the importance of the channel.

Zhitong FinanceDec 3 02:56 ET